Metabolic Rx (Repurposed) Cardiovascular Renal Neurological Hepatic

Semaglutide

Peptide

Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

Semaglutide carries some of the strongest human outcome evidence in the ClinEvident registry. Originally approved for type 2 diabetes (Ozempic) and obesity (Wegovy), it has demonstrated significant benefits across multiple organ systems in large randomized controlled trials.

The FLOW trial (NEJM 2024) showed a 24% reduction in composite kidney outcomes. The SELECT trial showed a 20% reduction in major cardiovascular events in non-diabetic adults with obesity. These are hard clinical endpoints from dedicated Phase 3 RCTs — the gold standard of evidence.

Critical safety note: GLP-1 therapy causes 30-40% lean mass loss alongside fat loss. Resistance training is a MANDATORY combination to prevent sarcopenia. Cold water immersion post-resistance training is directly counterproductive for GLP-1 patients.

Safety Considerations

30-40% of weight loss is lean mass without resistance exercise countermeasure. Resistance training is MANDATORY. GI side effects (nausea, vomiting) common in titration phase. Pancreatitis risk (rare). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Do not combine with cold water immersion post-resistance training.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Known Interactions (1)

🔒

Create a free account to see interaction data.

Create a free account

Products Containing Semaglutide

🔒

2 commercial products are listed for this molecule. Create a free account to see them, with each product's dose next to the evidence dose.

Create a free account

Regulatory Intelligence

🔒

Subscribe to access FDA enforcement history, third-party verification status, and regulatory risk assessment.

This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.